Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials

An unfortunate subset of hypertensive patients develops resistant hypertension in which optimal doses of three or more first-line antihypertensive drugs fail to sufficiently control blood pressure. Patients with resistant hypertension represent a high-risk and difficult-to-treat group, and such pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Alomar, Sara Abdulrahman, Alghabban, Sarah Ali, Alharbi, Hadeel Abdulaziz, Almoqati, Mehad Fahad, Alduraibi, Yazid, Abu-Zaid, Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839263/
https://www.ncbi.nlm.nih.gov/pubmed/33520782
http://dx.doi.org/10.4103/ajm.ajm_117_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839263/
https://www.ncbi.nlm.nih.gov/pubmed/33520782
http://dx.doi.org/10.4103/ajm.ajm_117_20

Ejemplares similares